Abzena PLC Block Listing Update (9080A)
04 January 2018 - 5:12AM
UK Regulatory
TIDMABZA
RNS Number : 9080A
Abzena PLC
03 January 2018
Abzena plc
Block Listing Update
Cambridge, UK, 3 January 2018 - Further to the announcement by
Abzena plc (AIM: ABZA, 'Abzena' or the 'Group') on 3 July 2017,
between 4 July 2017 and 3 January 2018, the Group announces that a
total of 213,227 ordinary shares of GBP0.002 each in the share
capital of the Group ('Ordinary Shares') have been issued pursuant
to the Group's 2013 Share Incentive Plan and admitted to trading in
accordance with the block listing applied for on 7 July 2015 (the
'Block Listing'). An update in accordance with Schedule 6 of the
AIM Rules for Companies is set out below. Abzena holds no shares in
treasury and hence the total number of current voting rights is
213,817,130.
BLOCK LISTING SIX MONTHLY RETURN
Name of applicant: Abzena plc
---------------------------------------------------- ----------------------------------------------------------------
Name of scheme: Abzena plc 2013 Share Incentive Plan
---------------------------------------------------- ----------------------------------------------------------------
Period of return: From: 4 July 2017 To: 3 January 2018
-------------------------- ------------------------ -------------------------- --------- -------------------------
Balance of unallotted securities under scheme(s)
from previous return: 757,476
---------------------------------------------------- ----------------------------------------------------------------
Plus: The amount by which the block scheme(s) has Nil
been increased since the date of the last
return (if any increase has been applied for):
---------------------------------------------------- ----------------------------------------------------------------
Less: Number of securities issued/allotted under
scheme(s) during period (see LR3.5.7G): 213,227
---------------------------------------------------- ----------------------------------------------------------------
Equals: Balance under scheme(s) not yet
issued/allotted at end of period 544,249
---------------------------------------------------- ----------------------------------------------------------------
Number and class of securities originally admitted 1,779,000 ordinary shares of GBP0.002 each, admitted on 13 July
and the date of admission 2015
---------------------------------------------------- ----------------------------------------------------------------
Name of contact: Julian Smith
---------------------------------------------------- ----------------------------------------------------------------
Telephone number of contact: +44 1223 903 498
---------------------------------------------------- ----------------------------------------------------------------
-Ends-
Enquiries:
Abzena plc
John Burt, Chief Executive
Officer
Julian Smith, Chief Financial
Officer +44 1223 903498
Numis (Nominated Adviser and
Broker)
Clare Terlouw / James Black
/ Paul Gillam +44 20 7260 1000
N+1 Singer (Joint Broker)
Aubrey Powell / Liz Yong +44 20 7496 3000
Instinctif Partners +44 20 7457 2020
Melanie-Toyne Sewell / Alex abzena@instinctif.com
Shaw
Notes to Editors
About Abzena
Abzena (AIM: ABZA) provides proprietary technologies and
complementary services to enable the development and manufacture of
biopharmaceutical products.
The term 'ABZENA Inside' is used by Abzena to describe products
that have been created using its proprietary technologies and are
being developed by its partners, and include Composite Human
Antibodies(TM) and ThioBridge(TM) Antibody Drug Conjugates (ADCs).
Abzena has the potential to earn future licence fees, milestone
payments and/or royalties on 'ABZENA Inside' products.
Abzena offers the following services and technologies across its
principal sites in Cambridge (UK), San Diego, California (USA) and
Bristol, Pennsylvania (USA):
-- Immunology research studies, including immunogenicity
assessment of candidate biopharmaceutical products;
-- Protein engineering to create humanized antibodies and deimmunised therapeutic proteins;
-- Cell line development for the manufacture of recombinant proteins and antibodies;
-- Contract process development and GMP manufacture of
biopharmaceuticals, including monoclonal antibodies and recombinant
proteins for preclinical and clinical studies;
-- Contract synthetic chemistry and bioconjugation research
services, focused on antibody-drug conjugates (ADCs);
-- Proprietary site-specific conjugation technologies and novel payloads for ADC development; and
-- GMP manufacturer of ADC linkers, payloads & combined linker-payloads.
For more information, please see www.abzena.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
BLRBJMPTMBBMBMP
(END) Dow Jones Newswires
January 03, 2018 13:12 ET (18:12 GMT)
Abzena (LSE:ABZA)
Historical Stock Chart
From Apr 2024 to May 2024
Abzena (LSE:ABZA)
Historical Stock Chart
From May 2023 to May 2024